EstroGel

Bioidentical Hormones vs. Standard HRT Standard HRT These are FDA-approved hormone medications that may contain: Synthetic hormones (like medroxyprogesterone acetate) Animal-derived hormones (like Premarin, made from pregnant mare urine) Chemically modified versions that work in your body similarly to natural hormones Bioidentical Hormones These have a molecular structure identical to hormones your body produces naturally. Many FDA-approved options exist, including: Estradiol patches (Vivelle-Dot, Climara) Estradiol gels (Divigel, Estrogel) Progesterone capsules (Prometrium - made from yams) The "Compounded" Distinction Some bioidentical hormones are custom-compounded by specialty pharmacies (like Women's International Pharmacy or Belmar Pharmacy), mixed to individual specifications - but these are not FDA-approved and have less quality oversight. Key Takeaway FDA-approved bioidentical options offer a good middle ground - natural molecular structure with regulatory oversight The marketing term "bioidentical" is sometimes overstated - what matters most is the type, dose, and delivery method Consult a menopause specialist (look for NAMS-certified practitioners) for personalized guidance.

Mentioned in position 5 of 8

Short answer: You may be in perimenopause if your periods and symptoms have started changing — most commonly irregular menstrual cycles along with hot flashes, sleep problems, mood changes, or vaginal dryness. The only way to be sure is to track symptoms and talk with your clinician for an evaluation. What perimenopause is Perimenopause is the transition before menopause when ovarian hormone (estrogen/progesterone) production becomes erratic. Menopause is defined after 12 consecutive months without a period; perimenopause is the years leading up to that. Common signs and symptoms Changes in your periods (irregular timing, heavier or lighter bleeding) Hot flashes and night sweats Sleep problems and fatigue Mood swings, anxiety, or low mood Vaginal dryness, pain with sex, decreased libido Trouble concentrating or “brain fog” Breast tenderness, headaches, weight gain Decreased fertility (can still get pregnant until menopause) When it typically happens Most people start perimenopause in their 40s (it can begin in the late 30s and last up to 10 years). Average length is about 4 years. Menopause average age is about 51. How to evaluate it Track your cycles and symptoms for a few months (apps like Clue or Flo make this easy). If still having periods and pregnancy is possible, do a pregnancy test first. See your primary care provider or gynecologist. They will: Review symptoms and medical history Do a physical exam and possibly a pelvic exam Order tests as needed: thyroid tests (TSH), CBC if heavy bleeding, iron studies, and sometimes hormone tests (FSH, estradiol). Note: FSH and estradiol vary during perimenopause, so a single test may not be definitive. When lab tests help and their limits FSH tends to rise as you approach menopause, but levels fluctuate in perimenopause. A single normal FSH does not rule out perimenopause. Clinicians most often diagnose perimenopause based on symptoms and bleeding patterns, not just one lab. Treatment and symptom relief (talk with your clinician about risks/benefits) Lifestyle: sleep hygiene, regular exercise, limit caffeine/alcohol, stop smoking (smoking causes earlier menopause). Vaginal dryness: water-based or silicone-based lubricants (Sliquid, Astroglide, K-Y) and vaginal moisturizers (Replens). These are safe, OTC options. Menstrual control and contraception if still having periods: combined oral contraceptives can regulate bleeding and provide contraception. A levonorgestrel IUD (Mirena) can reduce heavy bleeding and protect the uterus if you use estrogen therapy. Hormone therapy (most effective for hot flashes and night sweats): systemic estrogen (patches like Climara or Vivelle-Dot, gels such as EstroGel, or oral estradiol like Estrace) — usually given with progesterone (micronized progesterone: Prometrium) if the uterus is intact. HRT has benefits and risks (VTE, stroke, breast cancer risk varies by type/duration); it’s typically favored for symptomatic people under 60 or within 10 years of menopause but must be individualized. Non-hormonal prescription options for hot flashes: low-dose SSRIs/SNRIs (venlafaxine/Effexor) or paroxetine (Brisdelle—have interactions and pregnancy warnings), gabapentin (Neurontin), or clonidine. Discuss side effects and drug interactions with your clinician. For mood/sleep problems: consider CBT, therapy, and sleep hygiene; medications if needed. When to call a clinician or seek urgent care Very heavy bleeding (soaking a pad/tampon every hour), passing large clots, severe pelvic pain, dizziness or fainting — seek urgent care. New or worsening symptoms that affect daily life or raise safety concerns. Next steps I suggest Start tracking cycles and symptoms (Clue or Flo are easy choices). If you want evaluation/treatment: make an appointment with your PCP or gynecologist. If you want telehealth care, services like PlushCare or Nurx can connect you with a clinician for an initial visit and prescriptions in many areas. Bring a list of symptoms, how long they started, and any medications or family history of blood clots, stroke, breast cancer, or heart disease — these affect treatment choices. If you want, tell me: Your age, recent cycle pattern changes, and the top 2 symptoms bothering you most — I can help you decide what to track and what to bring up at your visit.

Mentioned in position 9 of 17

Short answer: for most people who need systemic estrogen, the transdermal route (patch or gel) is generally safer than oral estrogen—especially with regard to blood clots (venous thromboembolism) and some liver/metabolic effects. Why: Oral estrogens go through the liver first (“first‑pass”), which raises clotting factors, increasing VTE risk (and can raise triglycerides and affect CRP). Multiple studies and meta‑analyses show oral menopausal estrogen is associated with a higher VTE risk than transdermal. Transdermal estradiol (patch or gel) delivers hormone directly into the bloodstream, avoids the first‑pass hepatic effect, gives steadier blood levels, and is not associated with the same increase in VTE risk in observational studies. Oral estrogen may also increase gallbladder disease more than transdermal. Both routes carry other risks that depend on dose, whether a progestin is also used (required if you have a uterus), age, time since menopause, and personal risk factors (smoking, obesity, prior clots, thrombophilia, stroke, active cancer). Practical choices (brand examples): Transdermal patches: Climara, Vivelle‑Dot (Evra in some countries), Alora, Minivelle — commonly used for lower VTE risk and steady estradiol levels. Transdermal gels/solutions: EstroGel, Divigel — alternatives if you don’t like patches. Oral tablets: Estrace (micronized estradiol) or Premarin (conjugated equine estrogens) — used widely but have higher hepatic effects than transdermal. Other important points: If you have a history of VTE, known thrombophilia (e.g., factor V Leiden), recent stroke, or active liver disease, systemic estrogen may be contraindicated — and transdermal is usually preferred over oral only after specialist input. If you have a uterus, you’ll usually need a progestogen as well to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is often used and may have a different side‑effect profile than some synthetic progestins. Use the lowest effective dose for the shortest time needed and review periodically. Avoid unregulated “compounded bioidentical” products unless closely supervised (they’re not FDA‑standardized). Next step: discuss your personal medical history (age, smoking, clot history, cardiovascular risk, family history of thrombosis or breast cancer, whether you still have your uterus) with your clinician to choose route, dose, and whether you need progestogen. I can help you list questions to bring to your provider or summarize risks based on specific personal factors if you want.

Mentioned in position 6 of 10

Short answer: Bioidentical hormones can be safe and effective when they are medically appropriate, prescribed and monitored by a clinician, and — when possible — are FDA‑approved products. The safety profile is similar to conventional hormone therapy and depends on the hormone type, dose, route, timing (age/years since menopause) and your health risks. Many doctors warn against compounded “bioidentical” mixtures because they’re not FDA‑reviewed and can have dosing and purity problems. What “bioidentical” means “Bioidentical” simply means the hormone molecule is chemically identical to the hormone your body makes (for example, estradiol or micronized progesterone). FDA‑approved products (oral, patch, gel, vaginal) often use bioidentical estradiol or progesterone. The term is also used by promoters of custom-compounded hormone mixes, which is where confusion arises. What major medical groups and doctors say The North American Menopause Society (NAMS), ACOG (American College of Obstetricians and Gynecologists) and the Endocrine Society: bioidentical hormones that are FDA‑approved are acceptable and have known benefits/risks. They caution against compounded preparations because those lack the rigorous testing for purity, potency and consistent dosing. The FDA: warns consumers that compounded “bioidentical hormone” products may be unsafe and unapproved and that claims they are safer or more effective than FDA‑approved options are not supported by evidence. Benefits and risks (high level) Benefits: Relief of hot flashes, night sweats, vaginal dryness, and prevention of bone loss when used appropriately. Risks: Depending on type/dose/route and patient risk factors, there can be increased risk of blood clots, stroke, and (with some regimens and longer use) increased breast cancer risk. Transdermal (patch/gel) estradiol may carry lower clot risk than high‑dose oral estrogen for some women. Compounded BHRT risks: variable dosing, contamination, inaccurate labeling, and lack of clinical trial data supporting claimed advantages. FDA‑approved bioidentical products (examples doctors prefer) Estradiol oral: Estrace Estradiol transdermal patches: Climara, Vivelle‑Dot (and others) Estradiol gels: EstroGel Vaginal/local products for dryness: Vagifem (estradiol tablet), Estrace cream, Estring (vaginal ring) Micronized progesterone (bioidentical): Prometrium (Doctors prefer these because they are standardized, quality‑tested, and have safety/efficacy data.) Common problems with compounded BHRT No FDA review: potency, purity and sterility are not guaranteed the same way as manufactured drugs. Testing methods used by some compounding clinics (saliva hormone panels) are unreliable for guiding therapy. Marketing claims that compounded BHRT is “safer” or “anti‑aging” are not supported by evidence. What a reasonable, evidence‑based clinician will do Take your medical history and assess risks (family history of breast cancer, clotting disorders, heart disease). Discuss nonhormonal and lifestyle options first when appropriate. Prefer FDA‑approved bioidentical products when they meet your needs. Use the lowest effective dose for symptom control, reassess regularly, and monitor (mammography, cardiovascular risk factors, etc.). If a truly custom dose is needed (rare situations, allergy to excipients, or unique dosing not available commercially), refer to an accredited compounding pharmacy and give clear informed consent about unknowns/risks. If you’re considering BHRT — practical questions to ask Is this an FDA‑approved product or a compounded formulation? Why is this particular preparation being recommended? What are the expected benefits and the specific risks for me? How will you monitor effectiveness and side effects, and how often? Has the compounding pharmacy been accredited and does it follow USP standards? Bottom line Bioidentical hormones per se are not inherently safer or riskier than conventional hormones — it depends on the formulation and how they’re used. Most doctors recommend FDA‑approved products when possible and are cautious about compounded BHRT because of quality and evidence issues. Talk with a board‑certified gynecologist, endocrinologist or menopause specialist about your symptoms and risks before starting hormone therapy. If you want, tell me your age, symptoms and medical history (past blood clots, heart disease, breast cancer, smoking, etc.) and I can outline what a safe evaluation and treatment plan might look like.

Mentioned in position 4 of 7

BHRT Monthly Costs & Insurance Coverage Typical Monthly Costs The cost varies significantly by provider and treatment type: Treatment Type Monthly Cost Range Creams/gels (compounded) $30–$100 Oral capsules $25–$75 Patches $30–$80 (sometimes covered) Pellet therapy $300–$500 (every 3–6 months) Provider/monitoring fees $50–$200+ Insurance Coverage The honest answer is: it's complicated. FDA-approved bioidentical options (like Vivelle-Dot patches, Prometrium, EstroGel) are often covered by insurance Compounded BHRT is usually not covered because it's not FDA-approved Pellet therapy is almost universally out-of-pocket Recommended Providers to Consider Midi Health – telehealth, works with insurance, focuses on women's hormonal health Winona – transparent pricing, compounded BHRT, ~$99+/month Alloy – affordable, insurance-friendly options Local compounding pharmacies – often cheaper than clinic markups Money-Saving Tips Ask your regular OB/GYN or PCP to prescribe FDA-approved bioidenticals first Use GoodRx to reduce pharmacy costs HSA/FSA funds can typically be used Would you like more detail on any specific option?

Mentioned in position 3 of 7

Short answer If you want the safest, best‑studied option, ask first about evidence‑based (traditional) HRT using FDA‑approved products (estradiol ± a progestogen when you still have a uterus). BHRT (compounded “bioidentical” hormones) can be considered if you need a dose or formulation that’s not commercially available or you’ve had problems with standard products — but it’s less regulated and not proven safer or more effective. Why (brief) Traditional HRT: FDA‑approved products (brands and formulations) have known dosing, quality control, and safety data. Examples: estradiol patches (Vivelle‑Dot, Climara), estradiol gels (Divigel, EstroGel), oral estradiol (Estrace), vaginal estrogens (Vagifem, Estring). For progestogen: micronized progesterone (Prometrium) is a bioidentical, FDA‑approved option used to protect the uterus. BHRT / compounded hormones: marketed as “natural” and individualized; may be useful for unusual dosing or preparations. But compounded products are not FDA‑reviewed for consistency or purity, variable between pharmacies, and major menopause societies do not recommend them as first‑line for routine use. Which to ask your clinician for Start by discussing goals and risks with a clinician experienced in menopause. If you have no major contraindications and want symptom control, ask about: Transdermal estradiol (patch or gel) if you want stable blood levels and lower VTE risk (brands above). Add micronized progesterone (Prometrium) if you still have a uterus. Vaginal estrogen (Vagifem, Estring) for local genitourinary symptoms if systemic therapy isn’t needed. Consider BHRT only after discussing pros/cons and only via a prescriber who knows menopause care and uses an accredited compounding pharmacy. Where to go / who to ask Look for a NAMS‑certified menopause practitioner (North American Menopause Society) — they specialize in up‑to‑date HRT management. Good places to get thorough evaluation: academic menopause clinics (Mayo Clinic Menopause Clinic, Cleveland Clinic Women’s Health, Johns Hopkins Menopause Program) or a board‑certified gynecologist/endocrinologist with menopause experience. If you pursue compounded BHRT, use a reputable, accredited compounding pharmacy (look for PCAB/ACHC accreditation and certificates of analysis). Well‑known compounding pharmacies used by many clinicians include Wedgewood Pharmacy, Belmar Pharmacy, and Empower Pharmacy — but verify accreditation and quality documentation yourself. Practical points to discuss with the clinician Your symptoms, age, time since menopause, personal/family history of breast cancer, blood clots, heart disease, stroke. Whether you still have a uterus (determines need for progestogen). Route preference (patch/gel/oral/vaginal) — transdermal is often preferred if clot risk is a concern. Safety, duration, monitoring plan, and non‑hormonal alternatives (SSRIs/SNRIs, gabapentin, topical vaginal estrogen). If considering BHRT, insist on lab test validity (avoid saliva tests as sole basis), pharmacy accreditation, and a clear plan for follow‑up. If you’d like, tell me: your age, how long since menopause or last period, main symptoms, and any major health history (clotting, breast cancer, heart disease). I can suggest questions to bring to a clinician and which specific formulations are most likely to fit your situation.

Mentioned in position 4 of 11